{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:49:48Z","timestamp":1782452988844,"version":"3.54.5"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stiff-person syndrome (SPS) is a rare, antibody-mediated autoimmune disorder of the central nervous system, most frequently associated with antibodies against glutamic acid decarboxylase 65 (GAD65). Management of patients with an insufficient response to conventional immunotherapy remains a clinical challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 40-year-old woman with anti-GAD65 antibody-positive SPS. She experienced severe relapse and functional disability (modified Rankin Scale [mRS] score 4) despite plasma exchange and maintenance immunosuppression. We designed a sequential, mechanism-base regimen: the neonatal Fc receptor antagonist efgartigimod (3 cycles) was administered to rapidly reduce pathogenic IgG, followed by the anti-CD20 monoclonal antibody ofatumumab (2 cycles) to deplete B-cells and provide sustained immunomodulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This sequential strategy resulted in substantial and sustained clinical improvement (mRS score 4 to 1, Barthel Index 75 to 100) and a reduced clonazepam requirement despite persistently high anti-GAD65 antibody titers, demonstrating efficacy beyond mere antibody reduction. The regimen was well-tolerated with no significant adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case provides preliminary clinical experience with a sequential efgartigimod-ofatumumab strategy in treatment-resistant SPS. This approach, which combines rapid antibody clearance with sustained B-cell suppression, not only affirms the role of ofatumumab in long-term immunomodulation but also highlights the potential synergy of sequential administration, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1811565","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:45:01Z","timestamp":1782452701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential efgartigimod and ofatumumab for stiff-person syndrome: a case report illustrating a pathophysiology-informed strategy and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenxi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, The People\u2019s Hospital of Baiyun District","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, The People\u2019s Hospital of Baiyun District","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41582-024-01012-3","article-title":"Stiff-person syndrome and related disorders - diagnosis, mechanisms\u00a0and therapies","volume":"20","author":"Dalakas","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.41.10.1588","article-title":"Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome","volume":"41","author":"Brashear","year":"1991","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200109","article-title":"Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology","volume":"10","author":"Dalakas","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.11477\/mf.188160960770121365","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: challenges of standard treatments and prospects for new therapies","volume":"77","author":"Kuwabara","year":"2025","journal-title":"Brain Nerve Shinkei Kenkyu No Shinpo"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156971","article-title":"FcRn inhibitors in immune thrombocytopenia: a comprehensive review of therapeutic advances and clinical outcomes","volume":"193","author":"Nilforoushzadeh","year":"2025","journal-title":"Cytokine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/pgpm.s6840","article-title":"Ofatumumab: a novel monoclonal anti-CD20 antibody","volume":"3","author":"Lin","year":"2010","journal-title":"Pharmacogenomics Pers Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol Baltim Md 1950"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-009-0013-9","article-title":"Stiff person syndrome: advances in pathogenesis and therapeutic interventions","volume":"11","author":"Dalakas","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309201","article-title":"Stiff-person syndrome: insights into a complex autoimmune disorder","volume":"86","author":"Baizabal-Carvallo","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1232-z","article-title":"Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder","volume":"19","author":"Rakocevic","year":"2019","journal-title":"BMC Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.10.1531","article-title":"The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome","volume":"55","author":"Dalakas","year":"2000","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51791","article-title":"Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria","volume":"10","author":"Chia","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211003486","article-title":"GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions","volume":"14","author":"Tsiortou","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25002","article-title":"A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome","volume":"82","author":"Dalakas","year":"2017","journal-title":"Ann Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1387","article-title":"Evaluation of treatment outcomes in patients with stiff person syndrome with rituximab vs. standard of care","volume":"9","author":"Rineer","year":"2017","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/jnnp.2004.051144","article-title":"Treatment of stiff person syndrome with rituximab","volume":"76","author":"Baker","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00415-025-13157-2","article-title":"Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review","volume":"272","author":"Pignolo","year":"2025","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome","volume":"271","author":"Di Stefano","year":"2024","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02221.x","article-title":"GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence","volume":"15","author":"Skorstad","year":"2008","journal-title":"Eur J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240616","article-title":"Negative selection of multireactive B cell clones in normal adult mice","volume":"24","author":"Grandien","year":"1994","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41423-020-0510-z","article-title":"Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders","volume":"18","author":"Zou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12613","article-title":"Evaluation of the ability of immune humanized mice to demonstrate CD20-specific cytotoxicity induced by ofatumumab","volume":"12","author":"Semple","year":"2019","journal-title":"Clin Transl Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"B34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00415-025-13408-2","article-title":"Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study","volume":"272","author":"Yang","year":"2025","journal-title":"J Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12969-018-0278-1","article-title":"Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C \u03b4","volume":"16","author":"Lei","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1728721","article-title":"Ofatumumab-mediated CD20(+) B-cell depletion promotes neuromuscular junction functional recovery and sustains long-term efficacy in refractory generalized myasthenia gravis","volume":"16","author":"Ren","year":"2025","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"Kurrasch","year":"2013","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.27524","article-title":"Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I\/II study","volume":"62","author":"\u00d8stergaard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaut.2016.03.010","article-title":"B cell depletion with rituximab in patients with rheumatoid arthritis: multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens","volume":"70","author":"Cambridge","year":"2016","journal-title":"J Autoimmun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1710669","article-title":"B-cell-driven relapse and anti-CD20 rescue therapy after alemtuzumab in RRMS: case report and literature review","volume":"16","author":"Bruno","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011338","article-title":"Autologous hematopoietic stem cell transplantation for stiff-person spectrum disorder: a clinical trial","volume":"96","author":"Burt","year":"2021","journal-title":"Neurology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.09.024","article-title":"Subcutaneous immunoglobulin for maintenance therapy in stiff-person syndrome: one-year follow-up in two patients","volume":"30","author":"Fileccia","year":"2020","journal-title":"Neuromuscul Disord NMD"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:45:02Z","timestamp":1782452702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1811565"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1811565","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1811565"}}